Zamtocabtagene autoleucel reduced the risk of an event against R-GemOx in transplant-ineligible second-line large B-cell lymphoma, with serious …
Zamtocabtagene autoleucel reduced the risk of an event against R-GemOx in transplant-ineligible second-line large B-cell lymphoma, with serious …
Pozdeutinurad produced significant and durable urate lowering in uncontrolled gout, with treatment-emergent adverse-event rates close to placebo
Interim Phase 1b/2a results showed durable swallowing improvements at the low dose and larger three-month gains at the …
The interim Phase 1b dataset included eight efficacy-evaluable patients at cutoff, with post-cutoff confirmation lifting the reported rate …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the …
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances …
The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
Already a subscriber? Log in